Meeting
2019 ASCO Annual Meeting
A phase I study of the APE1 protein inhibitor APX3330 in patients with advanced solid tumors.
Authors
Safi Shahda
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN
Safi Shahda , Nehal J. Lakhani , Bert O'Neil , Drew W. Rasco , Jun Wan , Amber L Mosley , Hao Liu , Mark R. Kelley , Richard Adam Messmann
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics and Tumor Biology (Nonimmuno)
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
New Targets and New Technologies (non-IO)
Clinical Trial Registration Number
NCT03375086
Citation
J Clin Oncol 37, 2019 (suppl; abstr 3097)
DOI
10.1200/JCO.2019.37.15_suppl.3097
Abstract #
3097
Poster Bd #
89
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Phase 1 trial evaluating TTI-101, a first-in-class, orally bioavailable, small molecule, inhibitor of STAT3, in patients with advanced solid tumors.
First Author: Apostolia Maria Tsimberidou
Poster
2018 ASCO Annual Meeting
Phase I clinical trial of the glutaminase inhibitor CB-839 plus capecitabine in patients with advanced solid tumors.
First Author: Jennifer Rachel Eads
Poster
2024 ASCO Annual Meeting
A phase Ia/Ib, non-randomized, open-label, dose escalation and expansion trial of the B7-H6/CD3 T-cell engager BI 765049 with or without ezabenlimab in Asian patients with advanced solid tumors.
First Author: Toshihiko Doi
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Cohort expansion from the phase 1 JEWEL-101 study investigating the tissue factor-targeting antibody-drug conjugate XB002 in patients with advanced solid tumors: Pancreatic and esophageal cancer cohorts.
First Author: Susanna Varkey Ulahannan